Is capmatinib (Tabrecta) effective in treating the disease?

Introduction: Capmatinib (Tabrecta) is a specific MET receptor tyrosine kinase inhibitor with high oral bioavailability and high selectivity. It can effectively inhibit the phosphorylation of MET and MET-mediated downstream signaling proteins, thereby inhibiting the proliferation and migration of tumor cells, effectively inducing apoptosis, and exhibiting anti-tumor activity.

Can the generic version of Tabrecta be effective in treating diseases?

The generic version of Tabrecta can also be effective in treating diseases. Regarding the generic versions, due to different patent regulations in different countries and regions, generic versions of Tabrecta exist in some countries such as Laos and Bangladesh. These generic drugs may be more economical in price than the original drugs, and the generic drugs have been approved for marketing by relevant departments, indicating that their drug ingredients, mechanism of action, efficacy, etc. are basically the same as the original drugs.

When patients choose to use capmatinib (Tabrecta) generic drugs, they should ensure that the source is reliable and the quality is guaranteed, and it is best to use it under the guidance of a professional doctor. When choosing a generic drug, patients should consider the drug's origin, manufacturing quality and whether it has the appropriate regulatory approvals. In addition, because each patient's specific situation is different, the efficacy and safety of drugs will vary.

Therapeutic effect of capmatinib (Tabrecta)

In one study, 32 patients who had not received Tx treatment were included in 400 mg of capmatinib twice a day. The study showed that the patient's ORR was 68.8%, mDOR was 16.59 months, mPFS was 12.45 months, and mOS has not yet been reached. Common adverse reactions included peripheral edema (59.4%), nausea (37.5%), and increased serum creatinine (28.1%), and 2 patients (6.3%) discontinued treatment due to peripheral edema.

The price of the generic version of Tabrecta

The price of the generic version of Tabrecta varies depending on the manufacturer.

1. Laos Lucius version: The generic version of Capmatinib produced by Laos Lucius Pharmaceuticals is 200 mg x 60 tablets per box, and the price per box is about 2650$-3100$.

2. Bangladesh Everest version: Capmatinib produced by Bangladesh Everest is 200mg*56 capsules per box, and the price of a box is about 3600$-4000$.

The prices of these generic drugs are lower than those of original drugs, and they are more cost-effective. However, may vary due to market conditions, purchasing channels, exchange rate changes, manufacturers and other factors. The actual price should prevail when purchasing.